$VSTM

Calkins Daniel sold $17K of VSTM

Calkins Daniel (Chief Financial Officer) sold 4,089 shares of Verastem, Inc. (VSTM) at an average of $4.18 ($4.13–$4.18) across 2 trades on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Calkins Daniel
Published Jun 24, 2026, 8:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VSTM
Neutral
medium confidence
Mentioned
$VSTM
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider activity but does not include new operational, financial, or regulatory developments.

02

Market read

Traders may monitor whether this is part of a broader selling cadence, but the single, small 10b5-1 sale is unlikely to drive a major repricing.

03

What to watch

The sale size is small and explicitly pre-arranged; without additional context (e.g., repeated sales pattern, option exercises), the signal is limited.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-24 after-hours; reflects 2026-06-22 sale execution.

Background

This is an SEC Form 4 insider transaction for Verastem, Inc. (VSTM) by CFO Daniel Calkins.

Company-level read

Ticker impact

$VSTMNeutralMedium confidence
Context

Verastem CFO Daniel Calkins sold $17.1K of VSTM shares in an open-market transaction under a 10b5-1 plan, disclosed via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 insider sale with a stated 10b5-1 plan and modest dollar value relative to typical market moves.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with internal views on near-term risk; traders may still fade/trim on the headline if liquidity is thin.

Key entities

  • Verastem, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Daniel Calkins

    CFO who executed the open-market sale under a 10b5-1 plan.

Related articles

$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

$VSTMMed

Verastem, Inc. (VSTM): Results of Operations and Financial Condition

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622452d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 reg

$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

$VSTMMed

Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) shares rose after updated RAMP 205 pancreatic cancer trial data. The company reported 86% overall survival at six months and 68% progression-free survival at six months; 83% of patients had tumor shrinkage at the recommended phase 2 P2D dose, with no new safety signals. The update also noted 90% metastatic at diagnosis and 9 patients still on treatment.